Aneurysmal subarachnoid hemorrhage (SAH) is often a devastating event. However, therapeutic advances have added to the armamentarium for treating this malignant process. As case-fatality rates decline, attention is increasingly turned to the management of long-term complications. One of these is the enduring risk of recurrent SAH, which can occur despite successful endovascular or surgical treatment of the ruptured aneurysm.

Cumulative 8 to 10 year incidences of late rebleeding (more than one year after initial SAH) vary from 0.1 to 3.2 percent [1-5]. The risk of SAH recurrence has been estimated to be 15 to 22 times higher than the expected rate of a first SAH in a healthy age, sex matched cohort [2,4].

To continue reading this article, you must log in with your personal, hospital,
or group practice subscription. For more information or to purchase a personal subscription, click below on
the option that best describes you: